Valuation: Ironwood Pharmaceuticals, Inc.

Market Cap 800M 725M 670M 605M 1.14B 75.39B 1.18B 8.05B 3.19B 40.27B 3B 2.94B 128B P/E 2026 *
3.71x
P/E 2027 * 3.55x
Enterprise Value 800M 725M 670M 605M 1.14B 75.39B 1.18B 8.05B 3.19B 40.27B 3B 2.94B 128B EV / Sales 2026 *
1.62x
EV / Sales 2027 * 1.59x
Free-Float
96.77%
Yield 2026 *
-
Yield 2027 * -
1 day-0.41%
1 week+10.02%
Current month+38.00%
1 month+34.54%
3 months+18.38%
6 months+31.25%
Current year+43.32%
1 week 4.34
Extreme 4.345
5
1 month 3.38
Extreme 3.38
5
Current year 2.95
Extreme 2.95
5.78
1 year 2.95
Extreme 2.95
5.78
3 years 0.53
Extreme 0.5271
15.7
5 years 0.53
Extreme 0.5271
15.7
10 years 0.53
Extreme 0.5271
21.2
Manager TitleAgeSince
Chief Executive Officer 68 2021-03-11
Director of Finance/CFO 44 2026-05-14
Chief Tech/Sci/R&D Officer - 2026-07-19
Director TitleAgeSince
Director/Board Member 68 2021-06-03
Chairman 61 2019-03-31
Director/Board Member 56 2019-03-31
Date Insider Type Main position Quantity % Market Cap. Importance
9/15/26 Free

Director

3,694 0.0022%
7/20/26 Free

Chief Technology Officer

137,036 0.0832%
7/7/26 Sell

Chief Financial Officer

-127,890 0.0777%
Change 5-day change 1-year change 3-year change Capi.($)
-0.41%+10.02%+43.32%-48.56% 800M
+1.26%+6.61%+41.12%+135.59% 1,286B
+0.79%+3.45%+46.35%+93.56% 688B
+0.20%+1.28%+27.01%+112.80% 521B
-0.44%+3.69%+39.60%+69.51% 386B
+0.55%+0.70%+59.00%+44.20% 364B
-0.12%+0.74%+26.78%+58.43% 302B
+0.37%+0.37%+3.62%+36.44% 287B
-0.30%+1.14%+38.59%+74.61% 252B
+0.08%+0.71%+34.25%+124.32% 208B
Average +0.20%+3.90%+35.96%+70.09% 430B
Weighted average by Cap. +0.54%+3.26%+37.63%+96.20%

Financials

2026 *2027 *
Net sales 494M 447M 414M 373M 704M 46.54B 728M 4.97B 1.97B 24.86B 1.85B 1.81B 78.92B 504M 457M 423M 381M 719M 47.54B 744M 5.08B 2.01B 25.4B 1.89B 1.85B 80.61B
Net income 217M 197M 182M 164M 309M 20.47B 320M 2.19B 867M 10.93B 815M 797M 34.7B 236M 214M 198M 179M 337M 22.27B 349M 2.38B 943M 11.9B 887M 868M 37.77B
Net Debt - -
Projected Income Statement - Annual - Ironwood Pharmaceuticals, Inc.
Logo Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Employees
100
Date Price Change Volume
26-11-13 US$4.830 -0.41% 2,808,074
26-11-12 US$4.850 -0.41% 3,568,998
26-11-11 US$4.870 +1.25% 2,821,048
26-11-10 US$4.810 +2.78% 4,594,417
26-11-09 US$4.680 +6.61% 5,331,411
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Ironwood Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.830USD
Average target price
6.175USD
Spread / Average Target
+27.85%
  1. Stock Market
  2. Stocks
  3. IRWD Stock